ITTBioMed’s Post

Who said that you cannot public scientific articles while working in clinical trials? Take this world! You can do anything as long as you have a great team and an indefinite supply of coffee! It was a bumpy road full of unexpected twists and turns (just like in science), but eventually, it ended in success. Hopefully, our work will be a stepping stone for further development within the field of MSCs. #stemcell #science #innovation #biotech https://lnkd.in/dNsjeXEZ

The Development and Validation of Technology for Time Critical Genomic Testing (DEVOTE) Programme brings together academic, industry and clinical partners from across the region, and aims to create societal and economic impact by realising the potential of genomic testing for all. Prof. Bill Newman, Professor of Translational Genomic Medicine at The University of Manchester and Consultant in Genomic Medicine at Manchester University NHS Foundation Trust, and a researcher with the NIHR Manchester Biomedical Research Centre (BRC), said: “This is a great opportunity to enhance GM’s status as a world leader in creating genetic tests that can give rapid results in minutes. We expect that the DEVOTE projects will lead to the adoption of new tests by the NHS to make drug prescription safer and more effective. This will be good for patients and good for GM by creating jobs and a centre for investment in this cutting-edge science.” Find out more about DEVOTE and how this programme is underpinned by a shared ethos to reduce inequalities across communities, and building on assets already in existence within the #GreaterManchester system: https://bit.ly/3BOuD7m The DEVOTE programme is led by The University of Manchester and supported by Health Innovation Manchester in partnership with: 🤝 Manchester University NHS Foundation Trust 🤝 Health Innovation Manchester 🤝 genedrive 🤝 Chromition 🤝 APIS Assay Technologies Ltd. 🤝 EMQN CIC #weareHInM #DEVOTE #GM #innovation #genomics #genetics

A New Era for Genomics and Multiomics in the Baltics! #Interlux Group is proud to unveil an exciting partnership with Element Biosciences #Elembio, a pioneer in Genomics and Multiomics innovation! Starting now, we are the official distributor of #Elembio in Lithuania, Latvia, and Estonia. 🧬 With its cutting-edge #AVITI System, Element Biosciences is redefining the standards in Next-Generation Sequencing (NGS), Genomics and Multiomics research. The platform is celebrated globally for its unmatched data quality, short turnaround times (TAT), and affordability – offering exceptional value in its class. Moreover, the #AVITI System has been validated by leading researchers in the Genomics and Multiomics fields, ensuring its reliability and versatility for diverse applications. 🧬 One platform that grows with your research, the AVITI™ family offers flexible upgrade solutions, so you’re never locked into one instrument. Each of #Elembio suite of innovative #sequencing and Multiomic platforms – AVITI LT™, #AVITI, and #AVITI24 – empowers you with cutting-edge ABC technology and unparalleled performance with the flexibility to upgrade as your application and throughput needs grow. 👉 From accelerating discoveries in Genomics and Transcriptomics to supporting Multiomics integration, the #AVITI System empowers labs with high-performance tools to meet the growing demands of modern research. This partnership means we can now bring the #AVITI Systems to customers across the Baltics, helping researchers unlock new possibilities and push the boundaries of innovation 🌍. We’re excited to play a part in advancing Genomics, supporting breakthroughs in healthcare, science and more. Together with #Elembio, let’s make the impossible possible! 🧬 #InterluxGroup #Elembio #AVITISystem #Genomics #Multiomics #NGS #Innovation #LifeSciences #Baltics

Happy Friday all, As you might know, I am producing the Developability and Characterization stream of PepTalk 2025 next January in San Diego. We are excited to introduce, as part of the stream this year, the inaugural Machine Learning and Predictive Methods in Analytical Development symposium (https://lnkd.in/g5TbGZB4). Rapid advancement in computing capability and algorithmic tools in recent years means we now have the opportunity to accurately select and advance the right biologic molecules towards the clinic earlier in the pipeline than ever before. In this program we will explore new technologies and strategies for circumventing issues with aggregation, stability, and other key biophysical properties in silico. We will discuss curating and integrating diverse data types to create predictive models, understanding the role of structure- and simulation-guided predictive modelling in the space, and identifying outstanding gaps remaining in the field. This symposium will be an exciting and engaging forum for discussing the most important strategies for addressing development challenges before they arise.    Highlights include speakers from organizations such as:   Adimab, who will describe the production and benchmarking of in-house experimental training data and predictive models   Alloy Therapeutics, Inc., who will demonstrate successful examples of their combined in silico and in vitro workflows for lead candidate selection   AstraZeneca, who will present new data-driven strategies to inform high-throughput developability screen design and construct developability models   Boehringer Ingelheim, who will contemplate the need for community-wide biophysical and analytical data standards to support predictive modeling across the industry.   Genentech, who will present a series of case studies demonstrating the challenges still remaining in predicting high concentration behavior of protein therapeutics   Northwestern University, who will share recent developments in developing high-throughput assays to build new machine learning models of aggregation Scripps Research, who will share recent work on de novo design of membrane- embedded protein domains and their subsequent characterization Universitat Autònoma de Barcelona, who will unveil the latest version of their industry-leading structure-based aggregation prediction software The University of Edinburgh, who will provide insights on the challenges associated with leveraging existing databases resources to inform development of therapeutic peptides University of Oxford, who will showcase their curated database of therapeutic antibody properties and their associated tools for predictively assessing developability risks #CHIPepTalk #antibodies #biologics #ADC #nanoparticles #analytics #machinglearning #developabilityprediction #biophysics #biophysicalcharacterization #drugdiscovery #drugdevelopment #proteinscience

Exciting Growth in Next-Generation Sequencing! 🚀 📥 Download the PDF: https://lnkd.in/gu-WKqbY The sequencing by synthesis segment continues to dominate the Next-Generation Sequencing (NGS) landscape, accounting for the largest market share. This cutting-edge technology not only enhances accuracy and throughput but also paves the way for groundbreaking discoveries in genomics, personalized medicine, and more. As we look ahead, the Next-Generation Sequencing market is estimated to grow significantly, projected to reach USD 27.0 billion by 2027, up from USD 13.0 billion in 2022, with a remarkable growth rate of 15.7%. This growth reflects the increasing demand for NGS in research and clinical applications, underscoring its pivotal role in transforming healthcare. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China) Other Companies that are Operating in this Market Globally: Oscor Inc. Immunodiagnostic Systems (IDS) Amico Group of Companies Medica Corporation Hemex Health, Inc. Attieh Medico EUROIMMUN US Molbio Diagnostics Broncus Medical, Inc. Lumibird Medical - Quantel Medical, Ellex & Optotek IZI Medical Tribun Health Canadian Hospital Specialties Limited BioSerenity Wondfo USA Johari Digital Healthcare Limited Day Zero Diagnostics, Inc iThera Medical BioPerfectus Mortara Instrument Graham-Field (GF Health Products, Inc) biosurfit Heidelberg Engineering US Locamed Santé & Confort Tema Sinergie #NextGenerationSequencing #NGS #Genomics #HealthcareInnovation #Biotechnology #MarketGrowth

This is what a consortium meeting should look like. Some projects are simply unique. They bring together everything you care about, everything you’ve worked for. For me, NANOSPRESSO-NL is one of those rare opportunities. During my PhD in molecular biology, I witnessed the early promise of personalized nucleic acid therapeutics. Back then, they were more of a distant vision—a concept with extraordinary potential but what about the delivery? Now, I’m part of a team that’s turning that vision into reality, and even push its boundaries to design local production of nucleic acids nanomedicines at bedside. This project is not just advancing technology; we’re working to change the way nanomedicine is made and delivered, especially for rare diseases. With my background in engineering and a passion for innovative design, Nanospresso is also a fascinating challenge. Developing microfluidic systems, integrating cutting-edge cartridges with several blisters for lipis and RNA, and enabling production of high-quality lipid nanoparticles—this is the kind of hands-on problem-solving we all dream to work on. But what truly sets this project apart is its collaborative spirit. Nanospresso is a consortium filled with brilliant, generous people—engineers, biologists, clinicians, lawyers and regulators—from PhD students to Key Opinion Leaders of the field, and from academia to industry - who share ideas, challenge each other, and work together to make breakthroughs. As you can see in this video from our annual meeting in Utrecht last Friday, the discussions are rich, constructive, and always focused on moving forward with good humor and purpose. And no matter where this six-year journey takes us, the lessons we’re learning will resonate far beyond this project. From regulatory pathways to quality certification, from the potential of nucleic acid nanomedicine to its real-world applications, we’re creating a foundation of knowledge that will endure. NANOSPRESSO-NL is not yet another research project. I see it as a model of what great science and international collaboration should look like. To be part of something that combines bold innovation with such a strong commitment to patient impact is a privilege. I feel incredibly lucky to be part of this adventure on behalf of the European Technology Platform for Nanomedicine (ETPN Association). CC to my great colleagues Raymond Schiffelers Sabine Fuchs Floor Wolbers Mariona Estape Senti Maurits Westerik Marieke De Bruin Olivia Lewis Joyce Hoek Sven Even F. Borgos Peter Marin Van Hasselt Nadine Saber Sjoerd Hak Tony Gouriye Hanna Barriga Marta Luciani Kim Roekevisch Luca Panariello Bora Zwart Irem Bicerel Menno Grouls et al. #NanoEspresso #Nanomedicine #Innovation #Collaboration #RareDiseases #GameChanger

#4th Ace Drug Discovery Summit (ADDS) | London 2025👏 🗣️ACE EXPO LTD is thrilled to introduce our distinguished Sponsor Partner,10x Genomics, Joining us at the #4thADDS2025 in London on 2nd-3rd April 2025📆 10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 8,200 research papers, the innovative single-cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more. 10x Genomics talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology. 👉Learn More: https://lnkd.in/gEkhznG Don't miss this chance to connect with 10x Genomics and other industry leaders. Secure your spot at the Summit today. 📧 For details on VIP passes, our full speaker lineup, and registration, email us at info@acxpo.com 🌐 Or visit our website: https://lnkd.in/ddWbBCkC #drugdiscoveryinlondon #innovativeinsights #preclinical #validation #biomarkers #drugdiscovery #molecularbiology #biomarkers #assays #medicinalchemistry #ml #dataengineering #organicchemistry

𝐍𝐞𝐱𝐭-𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐒𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠! 🌟 📥 Download the Exclusive PDF: https://lnkd.in/gv7_kRDG Next-generation sequencing (NGS) is revolutionizing genomics, transforming the landscape of healthcare, research, and diagnostics. With its ability to analyze massive amounts of genetic data rapidly and accurately, NGS is paving the way for personalized medicine, disease prevention, and innovative research breakthroughs. The next-generation sequencing market is projected to grow significantly, with forecasts indicating a transformation from USD 13.0 billion in 2022 to USD 27.0 billion by 2027, driven by an impressive CAGR of 15.7%. This growth underscores the increasing demand for advanced genomic technologies across various sectors. As we continue to explore the potential of NGS, we can expect profound advancements in our understanding of genetics, ultimately leading to improved health outcomes and innovative treatments. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞: Illumina (US), Thermo Fisher Scientific (US), PerkinElmer (US), BGI Group (China), Agilent Technologies (US), Eurofins Scientific (Luxembourg), Pacific Biosciences (US), Oxford Nanopore Technologies (UK), QIAGEN (Netherlands), F. Hoffmann-La Roche AG (Switzerland), Brooks Automation (US), Psomagen, Inc. (US), 10x Genomics (US), Tecan Group (Switzerland), Zymo Research (US), Takara Bio (Japan), Promega Corporation (US), CD Genomics (US), New England Biolabs (US), and Novogene Corporation (China) Other Companies that are Operating in this Market Globally: Roche Sequencing USA GRAIL MEDGENOME Singular Genomics New England Biolabs CareDx, Inc. Ultima Genomics siParadigm Diagnostic Informatics Watchmaker Genomics Roche NimbleGen Inc. Clear Labs Molecular Testing Labs Progenesis Psomagen Hematogenix GENEWIZ from Azenta Life Sciences   Genotypic Technology Igentify National Institute for Communicable Diseases (NICD) Eurofins Genomics Gubra Hoora Pharma (Pvt.) Ltd. Macrogen Europe Nucleome Informatics Pvt Ltd #NextGenerationSequencing #NGS #Genomics #HealthcareInnovation #PersonalizedMedicine #MarketGrowth #FutureOfHealthcare

🗺️ Traditional tissue analysis is like a paper atlas—it shows you where things are. 🌎🔍 𝗦𝗽𝗮𝘁𝗶𝗮𝗹 𝗯𝗶𝗼𝗹𝗼𝗴𝘆, on the other hand, is like using Google Maps with street view: you see connections and real-time interactions (like live traffic updates!), diving deeper into every detail. This richer view helps us understand not just where cells are, but how they interact and function. We integrate spatial biology into our workflows to better understand mechanisms of action, discover new targets, and explore biomarkers of response with precision. For researchers and biopharma innovators, this means you get 𝗱𝗲𝗲𝗽𝗲𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗵𝗼𝘄 𝘆𝗼𝘂𝗿 𝗱𝗿𝘂𝗴 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗮𝗿𝗲 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗻𝗴 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲𝗶𝗿 𝗲𝗻𝘃𝗶𝗿𝗼𝗻𝗺𝗲𝗻𝘁, which helps in making faster, smarter decisions. For a deeper dive, don’t miss our latest white paper, 𝘐𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘧𝘳𝘰𝘮 𝘚𝘱𝘢𝘵𝘪𝘢𝘭 𝘉𝘪𝘰𝘭𝘰𝘨𝘺 𝘪𝘯 𝘋𝘳𝘶𝘨 𝘋𝘪𝘴𝘤𝘰𝘷𝘦𝘳𝘺 𝘢𝘵 𝘐𝘙𝘉𝘔: 𝘛𝘩𝘦 𝘐𝘮𝘱𝘢𝘤𝘵 𝘰𝘧 𝘊𝘦𝘭𝘭𝘶𝘭𝘢𝘳 𝘌𝘤𝘰𝘴𝘺𝘴𝘵𝘦𝘮𝘴 authored by Francesco Scalabrì , Ph.D. 👉 https://lnkd.in/eNWShsYm You may also join Francesco at the Inaugural Conference of the European Society for Spatial Biology (ESSB) on December 12-13 to discuss the latest advancements in the field. See you there! ~~~ 🔬 We’re IRBM, an Italian-based CRO partner specializing in early-stage drug discovery. All our work takes place at a single research site, enabling seamless collaboration to support preclinical research across various therapeutic areas. ➕ Follow us for practical insights into advancing drug discovery, updates on our capabilities, and the latest trends in preclinical innovation. #IRBM #DrugDiscovery #SpatialBiology #ESSB